Immune  	Immune  	 JJ	B-NP
checkpoint  	checkpoint  	 JJ	I-NP
blockade  	blockade  	 NN	I-NP
as  	as  	 IN	O
a  	a  	 DT	O
novel  	novel  	 NN	B-NP
immunotherapeutic  	immunotherapeutic  	 NN	I-NP
strategy  	strategy  	 NN	I-NP
for  	for  	 IN	I-NP
renal  	renal  	 JJ	I-NP
cell  	cell  	 NN	I-NP
carcinoma 	carcinoma 	 NNS	I-NP
:  	:  	 :	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
Renal  	Renal  	 JJ	I-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
RCC 	RCC 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
common  	common  	 JJ	O
genitourinary  	genitourinary  	 JJ	B-NP
malignancy 	malignancy 	 NN	I-NP
;  	;  	 :	O
when  	when  	 WRB	O
metastatic 	metastatic 	 NNS	B-NP
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
almost  	almost  	 RB	O
uniformly  	uniformly  	 RB	O
fatal 	fatal 	 JJ	O
.  	.  	 .	O
For  	For  	 IN	O
many  	many  	 JJ	O
years  	years  	 NNS	O
non-specific  	non-specific  	 JJ	B-NP
immunotherapy  	immunotherapy  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
mainstay  	mainstay  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
metastatic  	metastatic  	 JJ	B-NP
RCC 	RCC 	 NNP	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
led  	led  	 VBN	O
to  	to  	 TO	O
only  	only  	 RB	O
modest  	modest  	 JJ	O
success  	success  	 NN	O
and  	and  	 CC	O
significant  	significant  	 JJ	O
side-effects 	side-effects 	 NN	B-NP
.  	.  	 .	O
More  	More  	 RBR	O
recently 	recently 	 RB	O
,  	,  	 ,	O
seven  	seven  	 CD	O
targeted  	targeted  	 JJ	O
therapy  	therapy  	 NN	B-NP
drugs  	drugs  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
approved  	approved  	 VBN	O
to  	to  	 TO	O
treat  	treat  	 VB	O
metastatic  	metastatic  	 JJ	B-NP
RCC 	RCC 	 NNP	I-NP
;  	;  	 :	O
these  	these  	 DT	O
drugs  	drugs  	 NNS	O
impede  	impede  	 VBP	O
RCC  	RCC  	 JJ	B-NP
cell  	cell  	 NN	I-NP
growth 	growth 	 NN	I-NP
,  	,  	 ,	O
proliferation 	proliferation 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
angiogenesis  	angiogenesis  	 NNS	B-NP
and  	and  	 CC	O
have  	have  	 VBP	O
had  	had  	 VBN	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
impact  	impact  	 NN	O
on  	on  	 IN	O
patient  	patient  	 JJ	O
outcomes 	outcomes 	 NNS	O
,  	,  	 ,	O
but  	but  	 CC	O
with  	with  	 IN	O
infrequent  	infrequent  	 JJ	O
long  	long  	 JJ	O
term  	term  	 NN	B-NP
responders 	responders 	 NN	I-NP
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
renewed  	renewed  	 JJ	O
emphasis  	emphasis  	 NN	O
on  	on  	 IN	O
immunotherapy  	immunotherapy  	 NN	B-NP
has  	has  	 VBZ	O
emerged  	emerged  	 VBN	O
over  	over  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
several  	several  	 JJ	O
years  	years  	 NNS	O
with  	with  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
and  	and  	 CC	O
testing  	testing  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
novel  	novel  	 NN	O
class  	class  	 NN	O
of  	of  	 IN	O
immunotherapeutic  	immunotherapeutic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
called  	called  	 VBD	I-NP
checkpoint  	checkpoint  	 JJ	I-NP
inhibitors 	inhibitors 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
drugs  	drugs  	 NNS	O
have  	have  	 VBP	O
targeted  	targeted  	 VBN	O
the  	the  	 DT	O
programmed  	programmed  	 JJ	B-NP
cell  	cell  	 NN	I-NP
death  	death  	 NN	I-NP
1  	1  	 CD	I-NP
( 	( 	 -LRB-	O
PD-1 	PD-1 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
cytotoxic  	cytotoxic  	 JJ	B-NP
leukocyte  	leukocyte  	 NN	I-NP
antigen  	antigen  	 VBD	I-NP
4  	4  	 CD	I-NP
( 	( 	 -LRB-	O
CTLA-4 	CTLA-4 	 NNP	B-NP
)  	)  	 -RRB-	O
pathways  	pathways  	 NN	O
on  	on  	 IN	O
regulatory  	regulatory  	 JJ	B-NP
T  	T  	 NN	I-NP
cells 	cells 	 NNS	I-NP
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
immune  	immune  	 JJ	O
response  	response  	 NN	B-NP
enhancement  	enhancement  	 NN	I-NP
and  	and  	 CC	O
immune-mediated  	immune-mediated  	 JJ	O
anti-tumor  	anti-tumor  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
in  	in  	 IN	O
multiple  	multiple  	 JJ	O
malignancies 	malignancies 	 NN	O
,  	,  	 ,	O
including  	including  	 VBG	B-NP
RCC 	RCC 	 NNP	I-NP
.  	.  	 .	O
A  	A  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
studies  	studies  	 NNS	O
recently  	recently  	 RB	O
reported  	reported  	 VBD	O
utilizing  	utilizing  	 JJ	O
checkpoint  	checkpoint  	 JJ	B-NP
inhibitors 	inhibitors 	 NN	I-NP
,  	,  	 ,	O
either  	either  	 CC	O
alone  	alone  	 RB	O
or  	or  	 CC	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
other  	other  	 JJ	O
checkpoint  	checkpoint  	 JJ	B-NP
inhibitors  	inhibitors  	 NN	I-NP
or  	or  	 CC	O
vascular  	vascular  	 JJ	B-NP
endothelial  	endothelial  	 JJ	I-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
targeting  	targeting  	 VBG	I-NP
agents 	agents 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
these  	these  	 DT	O
studies  	studies  	 NNS	O
have  	have  	 VBP	O
shown  	shown  	 VBN	O
significant  	significant  	 JJ	O
and  	and  	 CC	O
at  	at  	 IN	O
times  	times  	 NNS	O
durable  	durable  	 JJ	O
responses  	responses  	 NNS	O
in  	in  	 IN	O
RCC  	RCC  	 NNP	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
has  	has  	 VBZ	O
led  	led  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
further  	further  	 JJ	O
phase  	phase  	 NN	O
I 	I 	 PRP	O
,  	,  	 ,	O
II 	II 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
III  	III  	 NNP	O
trials  	trials  	 NNS	O
and  	and  	 CC	O
this  	this  	 DT	O
review  	review  	 NN	O
will  	will  	 MD	O
discuss  	discuss  	 VB	O
the  	the  	 DT	O
history  	history  	 NN	O
and  	and  	 CC	O
currently  	currently  	 RB	O
available  	available  	 JJ	O
data  	data  	 NNS	O
for  	for  	 IN	O
immune  	immune  	 JJ	O
checkpoint  	checkpoint  	 JJ	B-NP
blockade  	blockade  	 NN	I-NP
in  	in  	 IN	O
RCC 	RCC 	 NNP	B-NP
.  	.  	 .	O
